Healthcare Panorama

Healthcare has always been dominant to the global economy though in recent times it has assumed a vital role in the pathway to economic recovery. This in turn, can provide pressing opportunities to investors. Every fortnight, our team, guided by an expert on healthcare, scan the most opportune openings for investing in Healthcare IT, Hospitals/Providers, Medtech, Multilaterals, Pharma, Biotech and diagnostic sectors. Whether established or newbies, their main aim is to secure a low-risk high reward. This report can be a one stop solution for reflecting on views and insights, on particular stocks in the growing industry of Health sector.

Features

✓ Inclusive Daily Analysis Report to keep up with the latest on what's hot and what's not, Our analysts give their views on the recent market movements and developments, and what it all means.

✓ Buy, sell and Hold recommendations.

✓ Access to the past recommendations and past reports.

✓ Risk rating: Low to Medium Volatility

 

Report Frequency : Fortnightly

Publishing Time : 2nd and 4th Wednesday

Price
Price | $1200 / 12 Months (Incl. of GST)

Our subscription comes with 14 days cooling-off period, however, it only applies to new subscribers.

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy and Financial Service Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.

  • visa
  • MasterCard
  • american express
  • google pay

We sell results, not just reports!

At Veye, we understand that making investment decisions can be a daunting task. That’s why we offer comprehensive market research on ASX stocks to help investors navigate the complexities of the market and make informed decisions about buying, selling or holding stocks. Our team of expert analysts conducts rigorous research and analysis to provide unbiased recommendations on a range of stocks across various industries. Our reports are designed to be accessible to all investors, regardless of their level of experience or financial expertise.

Subscribe Now

Past Recommendations

Code Avg. Buy Price Sell Price Gain/Loss
Fonterra Shareholders fund (FSF) $3.76 $4.68 45.19%
Black Cat Syndicate Limited (BC8) $0.308 $0.595 93.18%
Vysarn Limited (VYS) $0.355 $0.390 9.86%
Dropsuite Limited (DSE) $2.785 $4.51 61.94%
DXN Limited (DXN) $0.079 $0.06 -24.05%
PYC Therapeutics Limited (PYC) $0.92 $1.515 64.67%

Not every company performs as expected. Past performance is not an indication of future returns. “Gain/Loss” reflects movement in difference in average buy price and sell price plus dividends as a percentage of average buy price, and does not take into account costs or taxation."

Explore More

Frequently Asked Questions

- Different companies use different approaches to value a stock. It is always preferred to have a double check.

You will get recommendations through email and you will also get an access to daily analysis on our website.

- We recommend a company only after thorough research performed by our experts on the company’s past performance, future plans and a multitude of other financial aspects.

- After making the payment, you will receive an email containing your login credentials and an invoice. Your account will be created on veye.com.au, and you can use the login credentials to access your account. Once you log in, you will be able to access the reports that are available in your subscription.

What Our Clients Say About Us?

John Postle

This company has been good to deal with both professionally and honestly. The attention I have received from the company has been keeping me in front of the game and I am enjoying the experience. I recommend their services from my dealings with the company for the last 4 months.

John Postle
Guy Streeter Smith

Have regular talks and are looking at working together in the future.. have been with Veye for over two years and i am very happy hope to continue into the future.Have regular talks and are looking at working together in the future.. have been with Veye for over two years and i am very happy hope to continue into the future.

Guy Streeter Smith
Chris B.

As a long time fan of technical analysis, I appreciate that Veye presents this aspect of buying and selling shares in addition to informative financial aspects of individual stocks.

Chris B.